LumiraDx Limited announced that it signed a commercial distribution agreement with Axon Lab AG for the commercialization of its LumiraDx Platform and diagnostic tests to include exclusive distribution rights in Switzerland and additional non-exclusive distribution rights in further European countries to include and starting in Germany. Under the terms of the distribution agreement, LumiraDx has granted Axonlab the right to promote, market, and sell the LumiraDx Platform and tests to hospitals, doctors, clinics, private laboratories and research institutions in the aforementioned countries. The distribution agreement is effective immediately.

LumiraDx will continue its direct sales programs in its many active markets across the globe. Axonlab has dedicated diagnostics franchises and direct offices in the countries covered under the distribution agreement and is well positioned to accelerate the commercial success of the LumiraDx Platform in Switzerland and Germany.